What Ceclor SR 375 mg treats: main uses and benefits

Ceclor SR 375 mg is a sustained-release antibiotic containing cefaclor, a second-generation cephalosporin. This medication is designed to eliminate specific types of bacteria by interfering with the formation of their protective cell walls, which ultimately leads to the destruction of the bacteria causing the infection.

Primary Indications

This medication is primarily used to treat mild to moderate infections of the respiratory tract, urinary tract, and skin. Because it is a sustained-release formulation, the active ingredient is released gradually into the bloodstream, maintaining therapeutic levels over a longer period.

Commonly treated conditions include:

• Lower Respiratory Tract Infections: This includes acute bronchitis and secondary bacterial infections of chronic bronchitis, as well as pneumonia.
• Upper Respiratory Tract Infections: Such as pharyngitis (sore throat) and tonsillitis caused by susceptible strains of bacteria.
• Otitis Media: Middle ear infections, particularly when caused by common bacterial pathogens.
• Urinary Tract Infections: Including acute cystitis and pyelonephritis (kidney infection).
• Skin and Soft Tissue Infections: Such as cellulitis or abscesses caused by staphylococci or streptococci.
• Sinusitis: Acute infections of the paranasal sinuses.

Benefits of the Sustained-Release Formulation

The "SR" (Sustained Release) designation offers specific clinical advantages for patients:

• Steady Concentration: The gradual release helps maintain a consistent level of the antibiotic in the body, which is essential for effectively combating bacterial growth.
• Reduced Frequency: This formulation often allows for less frequent administration compared to immediate-release versions, which may assist in maintaining a regular treatment schedule.
• Targeted Efficacy: Cefaclor is effective against a broad spectrum of both Gram-positive and Gram-negative bacteria, making it a versatile option for various community-acquired infections.

Important Considerations for Use

Ceclor SR 375 mg is specifically active against bacterial infections only. It is not effective against viral infections such as the common cold or the flu. To ensure the infection is fully eradicated and to prevent the development of antibiotic resistance, it is standard practice to complete the full course of therapy as prescribed, even if symptoms improve shortly after starting the medication.

Official Regulatory Eligibility for Ceclor SR 375 mg

The eligibility profile for Ceclor SR 375 mg is defined by strict regulatory criteria, outlining populations that are permitted, restricted, or prohibited from using the sustained-release antibiotic.

These restrictions establish absolute non-eligibility for those with documented allergies, while imposing regulatory caution and conditional use for patient groups with specific age limits, compromised organ function, or relevant medical histories.

Interactions with other medicines and products

Regulatory documents identify specific interaction patterns for Cefaclor Monohydrate that involve pharmacokinetic and pharmacodynamic effects.

Pharmacokinetic and Exposure Effects

• Probenecid, a uricosuric agent, officially inhibits the renal excretion of Cefaclor. This interaction results in increased and prolonged serum concentrations of the antibiotic.
• Antacids containing magnesium or aluminum hydroxide must be taken with dose separation as co-administration within one hour may diminish Cefaclor absorption.

Pharmacodynamic and Co-administered Drug Efficacy

• Oral Anticoagulants, such as Warfarin, may exhibit an increased anticoagulant effect when combined with Cefaclor, with reports of increased prothrombin time. Monitoring of prothrombin time is officially advised during concomitant use.
• Cefaclor may decrease the effectiveness of hormonal contraceptives due to a documented effect on the intestinal flora.

Substance and Population Constraints

The regulatory documentation defines this product's interaction structure primarily through constraints on absorption timing and effects on systemic clearance and co-administered drug efficacy. These statements guide the understanding of concurrent administration requirements.

The mechanism of Cefaclor Monohydrate is defined by its targeted action on bacterial cell wall synthesis. The drug functions as a competitive inhibitor, binding covalently and irreversibly to crucial enzymes known as Penicillin-Binding Proteins (PBPs), specifically the D,D-Transpeptidases. This irreversible binding permanently blocks the cross-linking of the peptidoglycan polymer, resulting in the production of a structurally defective cell wall. This structural compromise triggers a mechanistic cascade involving the activation of the bacteria's own autolytic enzymes (autolysins). The weakened cell wall can no longer withstand the internal osmotic pressure, leading to cell swelling, rupture (lysis), and cell death. This sequence produces the drug's definitive bactericidal physiological effect. Furthermore, the Sustained-Release (SR) formulation ensures a prolonged concentration of Cefaclor, supporting the continuous inhibition required for this time-dependent killing mechanism.

Administration Method

Ceclor SR 375 mg tablets are designed for oral administration. To ensure the medication works as intended, the tablets should be swallowed whole with water. They should not be crushed, chewed, or broken, as this can interfere with the sustained-release mechanism of the formulation.

Timing and Food Intake

For optimal absorption of the active ingredient, this medication is typically taken with food. Maintaining a consistent schedule by taking the doses at the same time each day helps keep a steady level of the medicine in the body.

Duration of Use

It is standard practice to complete the full course of the medication as prescribed by a healthcare professional. Continuing the intake until the entire prescribed amount is finished is important for the effective management of the condition, even if symptoms appear to improve early in the process. Discontinuing the medication prematurely may result in the return of the original concerns.

Recent Clinical Evidence: Cefaclor

Clinical evidence has focused on cefaclor's sustained-release (SR) formulation, which was developed to investigate different dosing schedules for treating specific bacterial infections. The primary body of research evaluates the use of cefaclor SR 375 mg in adults for conditions such as mild-to-moderate infections of the lower respiratory tract, acute exacerbations of chronic bronchitis, and secondary bacterial infections of acute bronchitis.

Studies on Dosage and Administration

Research has explored the efficacy of administering the SR formulation twice daily, seeking to determine if this frequency can achieve plasma concentrations similar to the standard immediate-release formulation taken three times daily.

• Studies suggest that the total daily exposure (AUC) to the medication with the SR formulation administered twice daily aligns with the standard release form, which is a key parameter in antibiotic effectiveness.

Focus on Specific Infections

Trials have specifically investigated the use of cefaclor SR for:

Limitations of Current Data

Evidence remains limited on the use of cefaclor SR in pediatric populations; most published data relate to adult subjects. Furthermore, its efficacy for treating specific causative organisms, such as Haemophilus influenzae that produce beta-lactamase, may vary depending on regional resistance patterns. Research findings are specific to the study populations and conditions evaluated, and cannot be generalized to all bacterial infections.

Key Studies & References

1. Cefaclor extended-release tablets USP (DailyMed/NIH NLM)

Common questions about Ceclor SR 375 mg (FAQ)

Q: Does Ceclor SR 375 mg affect the birth control pill?

Official regulatory documents indicate that Cefaclor may decrease the effectiveness of hormonal contraceptives, which include birth control pills. This is thought to be due to the antibiotic's documented effect on the intestinal flora. If the medication is taken with oral anticoagulants, like Warfarin, official information states that the monitoring of prothrombin time (a measure of how quickly blood clots) may be advised by a healthcare professional.

Q: How should I store and dispose of this medicine?

The medication should be stored at Controlled Room Temperature, which is between 20 C to 25 C (68 F to 77 F), away from excess heat, moisture, and light. It must be kept in the original, tightly closed container. For disposal, unused or expired tablets must not be thrown away in household garbage or poured down the sink. Official guidance is to consult a pharmacist or local waste disposal service for the proper method of discarding the medicine.

Q: Is it safe to drink alcohol while taking Ceclor SR 375 mg?

Official regulatory documents for Ceclor do not list a specific interaction between the drug and alcohol (ethanol) that results in a severe reaction like flushing or vomiting. However, official labeling typically recommends consulting a healthcare provider about all substances, including alcohol, consumed while taking the medication.

Q: Does Ceclor SR cause sun sensitivity or sunburn?

The official list of adverse reactions includes various skin reactions such as rash and hives, and in rare cases, severe conditions like Stevens-Johnson syndrome. However, regulatory information does not specifically list photosensitivity (increased sensitivity to the sun) or sunburn as a documented adverse reaction to Ceclor SR.

Q: How long does Ceclor SR 375 mg take to start working?

Cefaclor is well absorbed after oral administration. The sustained-release (SR) formulation is specifically engineered to release the drug slowly over time to maintain a consistent therapeutic concentration for many hours, supporting continuous exposure for the targeted bacteria.

Q: Can I take Ceclor SR 375 mg while I am pregnant?

According to official regulatory labeling, the use of Ceclor SR during pregnancy is restricted. The medication should be administered only if clearly needed. This restriction is based on the fact that while animal studies have not shown harm to the fetus, there are no adequate and well-controlled studies in pregnant women.

Storage and Disposal of Ceclor SR 375 mg Extended-Release Tablets

Ceclor SR must be stored and handled according to specific conditions defined in regulatory labeling to maintain stability and prevent misuse.

Official Storage Requirements

The medication requires Controlled Room Temperature storage, maintained between 20 C to 25 C (68 F to 77 F). The tablets must be stored away from excess heat, moisture, and light.

For container requirements, the product must be kept in the original container and maintained tightly closed.

Handling and Disposal

The tablets must be stored out of the reach and sight of children.

Regulatory instructions for disposal state that unused or expired tablets must not be thrown away in household waste or wastewater. The proper method for discarding unused medicine is to consult a pharmacist.